New research indicates that paclitaxel, that is probably the most widely used chemotherapy for breast cancer tumors, suppresses tumors when offered at a dosage that is certain but at low doses, it really promotes cancer spread to the liver.
The findings claim that lowering the dosage of paclitaxel to lessen toxic side-effects is not a method that is safe.
"Paclitaxel and its analogous compounds will be the line that is first commonly utilized in medical cancer tumors chemotherapy. However, possible dangers and therapy that is reasonable of paclitaxel continue being widely examined," penned the authors of The FEBS Journal study.
Article: Low doses of paclitaxel enhance liver metastasis of breast cancer cells in the mouse model, Qi Li, Zhuang Ma, Yinhua Liu, Xiaoxi Kan, Changjun Wang, Bingnan Su, Yuchen Li, Yingmei Zhang, Pingzhang Wang, Yang Luo, Daxiang Na, Lanlan Wang, Guoying Zhang, Xiaoxin Zhu, Lu Wang, The FEBS Journal, doi: 10.1111/febs.13767, published 16 2016 june.